Literature DB >> 15613299

Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.

Christiane Ruedl1, Katrin Schwarz, Andrea Jegerlehner, Tazio Storni, Vania Manolova, Martin F Bachmann.   

Abstract

Virus-like particles (VLPs) are able to induce cytotoxic T-cell responses in the absence of infection or replication. This makes VLPs promising candidates for the development of recombinant vaccines. However, VLPs are also potent inducers of B-cell responses, and it is generally assumed that such VLP-specific antibodies interfere with the induction of protective immune responses, a phenomenon summarized as carrier suppression. In this study, we investigated the impact of preexisting VLP-specific antibodies on the induction of specific cytotoxic T-cell and Th-cell responses in mice. The data show that VLP-specific antibodies did not measurably reduce antigen presentation in vitro or in vivo. Nevertheless, T-cell priming was slightly reduced by antigen-specific antibodies; however, the overall reduction was limited and vaccination with VLPs in the presence of VLP-specific antibodies still resulted in protective T-cell responses. Thus, carrier suppression is unlikely to be a limiting factor for VLP-based T-cell vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613299      PMCID: PMC538584          DOI: 10.1128/JVI.79.2.717-724.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.

Authors:  Tazio Storni; Franziska Lechner; Iris Erdmann; Thomas Bächi; Andrea Jegerlehner; Tilman Dumrese; Thomas M Kündig; Christiane Ruedl; Martin F Bachmann
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

2.  Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.

Authors:  Christiane Ruedl; Tazio Storni; Franziska Lechner; Thomas Bächi; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

Review 3.  On cross-priming of MHC class I-specific CTL: rule or exception?

Authors:  Rolf M Zinkernagel
Journal:  Eur J Immunol       Date:  2002-09       Impact factor: 5.532

4.  A comparison of the responses of 100 infants to primary poliomyelitis immunization with two and with three doses of vaccine.

Authors:  F T PERKINS; R YETTS; W GAISFORD
Journal:  Br Med J       Date:  1959-04-25

5.  Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.

Authors:  D M Da Silva; D V Pastrana; J T Schiller; W M Kast
Journal:  Virology       Date:  2001-11-25       Impact factor: 3.616

6.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

Review 7.  HBV core particles as a carrier for B cell/T cell epitopes.

Authors:  P Pumpens; E Grens
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

Review 8.  Neonatal and early life vaccinology.

Authors:  C A Siegrist
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

9.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

10.  Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.

Authors:  Alexis M Kalergis; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  23 in total

1.  Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events.

Authors:  Konstantina Katsarou; Alexandros Alpha Lavdas; Panagiota Tsitoura; Elisavet Serti; Panagiotis Markoulatos; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

2.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.

Authors:  Jean-Noel Billaud; Darrell Peterson; Byung O Lee; Toshiyuki Maruyama; Antony Chen; Matti Sallberg; Fermin Garduño; Phillip Goldstein; Janice Hughes; Joyce Jones; David Milich
Journal:  Vaccine       Date:  2006-11-17       Impact factor: 3.641

4.  In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity.

Authors:  Ana Villegas-Mendez; Marina I Garin; Estela Pineda-Molina; Eugenia Veratti; Juan A Bueren; Pascal Fender; Jean-Luc Lenormand
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

5.  Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis.

Authors:  Florian Krammer; Theresa Schinko; Paul Messner; Dieter Palmberger; Boris Ferko; Reingard Grabherr
Journal:  J Virol Methods       Date:  2010-03-19       Impact factor: 2.014

6.  Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus.

Authors:  Kristopher J Koudelka; Chris S Rae; Maria J Gonzalez; Marianne Manchester
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

7.  Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer.

Authors:  Min Li; Uddalak Bharadwaj; Rongxin Zhang; Sheng Zhang; Hong Mu; William E Fisher; F Charles Brunicardi; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

8.  Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs.

Authors:  L Buonaguro; M L Tornesello; George K Jewis; F M Buonaguro
Journal:  AIDS Res Hum Retroviruses       Date:  2009-08       Impact factor: 2.205

9.  Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers.

Authors:  S Cho; S Dong; K N Parent; M Chen
Journal:  J Drug Target       Date:  2015-08-25       Impact factor: 5.121

10.  Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles.

Authors:  L Buonaguro; M L Tornesello; R C Gallo; Franco M Marincola; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.